Two year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing subcutaneous and sublingual immunotherapy.
BACKGROUND
Both SCIT (subcutaneous immunotherapy) and SLIT (sublingual immunotherapy) have clinical and immunologic efficacy in children with rhinitis and asthma but comparative studies are scarce.


OBJECTIVE
To investigate the clinical and immunological efficacy of mite-specific SLIT and SCIT in children with rhinitis and asthma.


METHODS
Thirty children monosensitized to house dust mite were randomized to receive either active SCIT or SLIT or placebo for 1 yr in a double-blind double-dummy placebo controlled design (Yukselen A et al., Int Arch Allergy Immunol 2012; 157:288-298). Thereafter, the placebo group was randomized to receive SCIT or SLIT, and for 1 yr all patients received active treatment with SCIT or SLIT. Symptom scores, drug usage, titrated skin prick tests, nasal and bronchial allergen provocation doses, serum house dust mite-specific immunglobulin E, sIgG4, IL-10 and IFN- g levels were evaluated.


RESULTS
The reduction of clinical scores with SLIT was more evident after 2 years of treatment in comparison to both the baseline and DBPC phase of the study. The change in titrated skin prick tests and nasal provocative doses was more prominent with both SCIT and SLIT at the end of the open phase. Although the increase inbronchial provocative doses was not significant at the end of the first year of treatment with SLIT, it reached a statistically significant difference after two years of treatment.


CONCLUSIONS
The clinical efficacy of SLIT is more prominent at the end of the second year, although this improvement is observed from the first year of treatment with SCIT in mite-sensitive children.
Clinic of Pediatric Allergy and Immunology, Children's Hospital of Gaziantep, Gaziantep, Turkey.
Ayfer
A
Yukselen
Seval Güneser
SG
Kendirli
Mustafa
M
Yilmaz
Derya Ufuk
DU
Altintas
Gulbin Bingol
GB
Karakoc
D000286:Administration, Sublingual; D000293:Adolescent; D000818:Animals; D001249:Asthma / Q000097:blood / Q000276:immunology / Q000628:therapy*; D001985:Bronchial Provocation Tests; D002648:Child; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood / Q000276:immunology; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D007167:Immunotherapy; D007279:Injections, Subcutaneous; D007371:Interferon-gamma / Q000097:blood / Q000276:immunology; D016753:Interleukin-10 / Q000097:blood / Q000276:immunology; D008297:Male; D009299:Nasal Provocation Tests; D039981:Pyroglyphidae; D065631:Rhinitis, Allergic; D012221:Rhinitis, Allergic, Perennial / Q000097:blood / Q000276:immunology / Q000628:therapy*
C573415:IFNG protein, human; C508609:IL10 protein, human; D007074:Immunoglobulin G; D016753:Interleukin-10; D007073:Immunoglobulin E; D007371:Interferon-gamma